Tiziana Life Sciences Ltd (NASDAQ:TLSA - Get Free Report) saw a significant growth in short interest in March. As of March 15th, there was short interest totalling 808,600 shares, a growth of 42.5% from the February 28th total of 567,600 shares. Based on an average daily volume of 979,300 shares, the short-interest ratio is currently 0.8 days. Approximately 1.1% of the shares of the stock are short sold.
Institutional Investors Weigh In On Tiziana Life Sciences
A number of institutional investors and hedge funds have recently made changes to their positions in TLSA. Bison Wealth LLC acquired a new position in shares of Tiziana Life Sciences during the 4th quarter worth about $30,000. Zhang Financial LLC grew its holdings in shares of Tiziana Life Sciences by 34.3% during the fourth quarter. Zhang Financial LLC now owns 93,187 shares of the company's stock worth $65,000 after buying an additional 23,800 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Tiziana Life Sciences by 12.4% in the fourth quarter. Geode Capital Management LLC now owns 245,722 shares of the company's stock valued at $171,000 after purchasing an additional 27,041 shares during the last quarter. Finally, Sanctuary Advisors LLC bought a new stake in Tiziana Life Sciences during the 3rd quarter worth about $864,000.
Tiziana Life Sciences Stock Performance
TLSA stock traded down $0.07 during trading on Thursday, hitting $1.04. The company had a trading volume of 228,572 shares, compared to its average volume of 452,376. The firm has a 50-day moving average price of $1.04 and a 200-day moving average price of $0.95. Tiziana Life Sciences has a 12 month low of $0.41 and a 12 month high of $1.91.
About Tiziana Life Sciences
(
Get Free Report)
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.
See Also
Before you consider Tiziana Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tiziana Life Sciences wasn't on the list.
While Tiziana Life Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
